Yellow fever vaccine supply: A possible solution

The Lancet

Volumn 387, Issue 10028, 2016, Pages 1599-1600

  Monath, Thomas P ^a   Woodall, Jack P ^b   Gubler, Duane J ^c   Yuill, Thomas M ^d   MacKenzie, John S ^e   Martins, Reinaldo M ^f   Reiter, Paul ^g   Heymann, David L ^h  

^a NewLink Genetics Corporation   (United States)

^b International Society for Infectious Diseases   (United States)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e CURTIN UNIVERSITY   (Australia)

^f Instituto de Technologia em Imunobiologicos   (Brazil)

^g INSTITUT PASTEUR   (France)

^h LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

YELLOW FEVER VACCINE;

ANGOLA; DEMOCRATIC REPUBLIC CONGO; FATALITY; HUMAN; MASS IMMUNIZATION; NIGERIA; NOTE; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; VACCINATION; VECTOR CONTROL; WORLD HEALTH ORGANIZATION; YELLOW FEVER; DOSE RESPONSE; SUPPLY AND DISTRIBUTION;

DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HUMANS; VACCINATION; YELLOW FEVER; YELLOW FEVER VACCINE;

EID: 84963701125     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)30195-7     Document Type: Note

References (15)

1. The Lancet Yellow fever: a global reckoning Lancet 387 2016 1348
2. WHO Dengue and severe dengue http://www.who.int/mediacentre/factsheets/fs117/en/ March, 2016 (accessed April 11, 2016).
3. WHO Dengue control: chikungunya http://www.who.int/denguecontrol/arbo-viral/other-arboviral-chikungunya/en/ 2016 (accessed April 11, 2016).
4. TP Monath, M Gershman, JE Staples et al. Yellow fever S Plotkin W Orenstein P Offit Vaccines 6th edn. 2013 Saunders Elsevier Philadelphia 870 968
5. KM De Cock, TP Monath, A Nasidi et al. Epidemic yellow fever in eastern Nigeria, 1986 Lancet 1 1988 630 633
6. A Nasidi, TP Monath, K De Cock et al. Urban yellow fever epidemic in western Nigeria, 1987 Trans R Soc Trop Med Hyg 83 1989 401 406
7. WHO Emergencies preparedness, response yellow fever http://www.who.int/csr/don/archive/disease/yellow-fever/en/ 2016 (accessed April 11, 2016).
8. WHO Disease outbreak news 6 April 2016 yellow fever - China http://www.who.int/csr/don/6-april-2016-yellow-fever-china/en/ (accessed April 8, 2016).
9. WHO Regional Office for South-East Asia Informal expert consultation on yellow fever threat to India and other SEA region countries. Report of the Consultation, Goa, India, March 23-25, 2011 2012 World Health Organization New Delhi 39
10. WHO Yellow fever vaccine: a global partnership http://www.who.int/csr/disease/yellowfev/global-partnership/en/#icg (accessed April 11, 2016).
11. J Hickling, R Jones Yellow fever vaccination: the potential of dose-sparing to increase vaccine supply and availability 2013 PATH Seattle, WA 118
12. RM Martins, L Maia M de, RH Farias et al. 17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study Hum Vaccin Immunother 9 2013 879 888
13. AC Campi-Azevedo, P de Almeida Estevam, JG Coelho-dos-Reis et al. Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline BMC Infect Dis 14 2014 391
14. E Gotuzzo, S Yactayo, E Cordova Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years Am J Trop Med Hyg 89 2013 434 444
15. WHO WHO Emergency use assessment and listing procedures for medical products during public health emergencies http://www.who.int/medicines/news/public-consult-med-prods/en/ (accessed April 11, 2016).